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Clinical, pathological and functional
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Andreea Manole,1,2 Zane Jaunmuktane,3 Iain Hargreaves,4 Marthe H. R. Ludtmann,1
Vincenzo Salpietro,1,2 Oscar D. Bello,5 Simon Pope,4 Amelie Pandraud,1,2 Alejandro Horga,2
Renata S. Scalco,2 Abi Li,6 Balasubramaniem Ashokkumar,1,7 Charles M. Lourenc¸o,8
Simon Heales,9 Rita Horvath,10 Patrick F. Chinnery,11,12 Camilo Toro,13
Andrew B. Singleton,14 Thomas S. Jacques,15 Andrey Y. Abramov,1 Francesco Muntoni,16
Michael G. Hanna,1,2 Mary M. Reilly,1,2 Tamas Revesz,1,6 Dimitri M. Kullmann,5
James E. C. Jepson5 and Henry Houlden1,2
Brown-Vialetto-Van Laere syndrome represents a phenotypic spectrum of motor, sensory, and cranial nerve neuropathy, often with
ataxia, optic atrophy and respiratory problems leading to ventilator-dependence. Loss-of-function mutations in two riboflavin
transporter genes, SLC52A2 and SLC52A3, have recently been linked to Brown-Vialetto-Van Laere syndrome. However, the
genetic frequency, neuropathology and downstream consequences of riboflavin transporter mutations are unclear. By screening
a large cohort of 132 patients with early-onset severe sensory, motor and cranial nerve neuropathy we confirmed the strong genetic
link between riboflavin transporter mutations and Brown-Vialetto-Van Laere syndrome, identifying 22 pathogenic mutations in
SLC52A2 and SLC52A3, 14 of which were novel. Brain and spinal cord neuropathological examination of two cases with
SLC52A3 mutations showed classical symmetrical brainstem lesions resembling pathology seen in mitochondrial disease, including
severe neuronal loss in the lower cranial nerve nuclei, anterior horns and corresponding nerves, atrophy of the spinothalamic and
spinocerebellar tracts and posterior column–medial lemniscus pathways. Mitochondrial dysfunction has previously been implicated
in an array of neurodegenerative disorders. Since riboflavin metabolites are critical components of the mitochondrial electron
transport chain, we hypothesized that reduced riboflavin transport would result in impaired mitochondrial activity, and confirmed
this using in vitro and in vivo models. Electron transport chain complex I and complex II activity were decreased in SLC52A2
patient fibroblasts, while global knockdown of the single Drosophila melanogaster riboflavin transporter homologue revealed
reduced levels of riboflavin, downstream metabolites, and electron transport chain complex I activity. This in turn led to abnormal
mitochondrial membrane potential, respiratory chain activity and morphology. Riboflavin transporter knockdown in Drosophila
also resulted in severely impaired locomotor activity and reduced lifespan, mirroring patient pathology, and these phenotypes could
be partially rescued using a novel esterified derivative of riboflavin. Our findings expand the genetic, clinical and neuropathological
features of Brown-Vialetto-Van Laere syndrome, implicate mitochondrial dysfunction as a downstream consequence of riboflavin
transporter gene defects, and validate riboflavin esters as a potential therapeutic strategy.
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Introduction
Brown-Vialetto-Van Laere (BVVL) syndrome is an auto-
somal recessive neurological disorder first described by
Brown in 1894 and later by Vialetto and Van Laere
(Brown, 1894; Vialetto, 1936; Van Laere, 1966). Affected
patients mostly present with neuropathy, bilateral sensori-
neural deafness, bulbar palsy and respiratory compromise.
Other cranial nerve palsies, optic atrophy, upper and lower
motor neuron involvement and ataxia can occur particu-
larly as disease progresses, mimicking conditions such as
amyotrophic lateral sclerosis (ALS), Madras motor
neuron disease and Nathalie syndrome (Anand et al.,
2012; Manole et al., 2014). Deafness is the most
common sign of this condition, with most affected individ-
uals exhibiting hearing loss during the disease course. The
time between the onset of deafness and the development of
other manifestations varies but is usually in early childhood
(Manole and Houlden, 2015).
Previous work has revealed strong links between muta-
tions in two genes (SLC52A2 and SLC52A3) and BVVL
syndrome, both of which encode riboflavin transporters
(Green et al., 2010; Johnson et al., 2012; Foley et al.,
2014). The role of another riboflavin transporter-encoding
gene, SLC52A1, in BVVL syndrome pathogenicity is still
uncertain, as it was found to be defective in only one case
(Ho et al., 2011). SLC52A2 and SLC52A3 mutations
include missense, nonsense, frame-shift, and splice-site al-
terations, but uniformly result in loss-of-function through
reduced riboflavin transporter expression and/or riboflavin
uptake (Foley et al., 2014; Udhayabanu et al., 2016).
Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine; vitamin
B2) is a water-soluble compound and acts as a precursor
for flavin mononucleotide (FMN) and flavin adenine di-
nucleotide (FAD). Both FMN and FAD function in biolo-
gical redox reactions such as in the mitochondrial electron
transport chain (ETC) (Powers, 2003). Since riboflavin
cannot be synthesized by mammals de novo, riboflavin
transporters are indispensable for normal cellular metabol-
ism, suggesting that reduced intracellular riboflavin is a
critical pathological mediator of BVVL syndrome. Indeed,
although infants with early-onset riboflavin transporter de-
ficiency rapidly become ventilator-dependent and usually
die in the first year of life, treatment with high-dose ribo-
flavin supplementation partially ameliorates the progression
of this neurodegenerative condition, particularly if initiated
soon after the onset of symptoms (Foley et al., 2014). In a
recent paper by Rizzo et al. (2017), motor neurons from
induced pluripotent stem cells (iPSCs) were derived from
two patients with BVVL syndrome carrying either
SLC52A2 or SLC52A3 mutations. They found a reduction
in axon elongation coupled with perturbations in neurofila-
ment composition and reduced autophagic/mitophagic flux.
However, despite these findings the pathophysiological
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mechanisms underlying motor neuron degeneration in
BVVL syndrome are still unclear.
Motor neurons are thought to be uniquely susceptible to
impaired energy metabolism because of their high meta-
bolic rate and axonal length (Cozzolino and Carri, 2012).
Furthermore, mitochondrial perturbations causing alter-
ation of the ETC and increased oxidative stress are thought
to be involved in the pathomechanisms of neurodegenera-
tion in some motor neuron diseases such as ALS or spinal
muscular atrophy (Johnson et al., 2010; Cozzolino and
Carri, 2012; Bartolome et al., 2013). Given the critical
role of riboflavin in the generation of substrates used for
the ETC, we hypothesized that reduced riboflavin transport
results in impaired ETC, which may in turn contribute to
neurodegeneration.
Here, we expand the clinic-genetic spectrum of riboflavin
transporter genes and then perform a series of experiments
to identify the underlying effects of loss of riboflavin trans-
porter function on neuronal integrity and mitochondrial
function. We review clinical case histories and undertake
pathological evaluation of brain and spinal cord of two
patients with confirmed SLC52A3 mutations who pre-
sented either in infancy or in later childhood. Finally, we
investigate the in vitro cellular effects of SLC52A2 muta-
tions on metabolism and ETC function and also the in vivo
consequences of loss of the SLC52A2/SLC52A3 homologue
in Drosophila melanogaster, and test whether these can be
mitigated by supplementation with a riboflavin derivative.
Materials and methods
Study subjects
Patients were enrolled and informed consent from the patient
and/or their parental guardian was obtained. DNA was col-
lected from a total of 132 suspected cases (probands and their
relatives) presenting with cranial neuropathies and sensori-
motor neuropathy with or without respiratory insufficiency.
Patients’ DNA samples were collected at medical centres in
England (including from patients originating from Pakistan,
India, Saudi Arabia, Kuwait, Iran and Turkey) as well as
from medical centres in Wales, Scotland, Northern Ireland,
Ireland, France, Belgium, the Netherlands, Greece, Malta,
Russia, Lebanon, Iceland, Australia and the USA, following
the announcement of an on-going molecular study at the
UCL Institute of Neurology, University College London
(National Hospital for Neurology and Neurosurgery, Queen
Square, London) of patients presenting with this phenotype.
This study was ethically approved by the UCL/University
College London Hospital Joint Research Office (99/N103),
and written informed consent to perform a skin biopsy and
fibroblasts was obtained as appropriate.
PCR and Sanger sequencing
Primer sequences, PCR and Sanger sequencing conditions for
SLC52A1, SLC52A2 and SLC52A3 were as in Foley et al.
(2014). Segregation of pathogenic variants was also assessed.
Where one heterozygous mutation was identified, deletions in
the other allele were investigated by array CGH (comparative
genomic hybridization) but no deletions or insertions were iden-
tified. Mutation positions are based on NCBI reference sequences
for complementary DNA. SLC52A2 mutation positions are
based on sequences NM_024531.4 for the nucleotide sequence
and NP_078807.1 for the protein sequence. SLC52A3 mutation
positions are based on sequences NM_033409.3 for the nucleo-
tide sequence, and NP_212134.3 for the protein sequence.
Neuropathological evaluation
Formalin-fixed, paraffin-embedded brain and spinal cord tissue
were available from two patients (Patients AM2 and AM4).
The paraffin sections were cut at 4mm thickness, mounted on
glass slides and stained with routine haematoxylin and eosin,
and Luxol fast blue/cresyl violet histochemical stains. Sections
were examined by immunohistochemistry with the following
antibodies: rabbit anti-glial fibrillary acid protein (GFAP) (poly-
clonal, 1:2500, Dako), mouse anti-phosphorylated neurofila-
ments (clone SMI31, 1:5000, Sternberg), mouse anti-myelin
basic protein (clone SMI94, 1:2000, Sternberg), rabbit anti-ubi-
quitin (polyclonal, 1:1200, Dako), mouse anti-p62 (3/P62LCK
Ligand, 1:100, BD Transduction), mouse anti--synuclein
(clone KM51, 1:50, Leica/Novocastra), mouse anti-amyloid-b
(clone 6F3D, 1:100, Dako), mouse anti-hyperphosphorlyated
tau (clone AT8, 1:1200, Innogenetics), mouse anti-TDP43
(clone 2E2-D3, 1:3000, Abova), mouse anti-CD68 (clone PG-
M1, 1:100, Dako), mouse anti-CD3 (LN10, 1:100, Leica/
Novocastra), mouse anti-CD20 (clone 7D1, 1:200, Dako).
Immunohistochemistry was carried out either manually or on
a BOND-MAX autostainer (Leica Microsystems) using 3,30-
diaminobenzidine as chromogen. Negative controls were trea-
ted identically except that the primary antibody was omitted.
Appropriate positive controls were used for all immunohisto-
chemical studies.
SLC52A2 patient fibroblasts
For further details of the generation of human fibroblast cul-
tures and cell culture, determination of flavin status in fibro-
blasts, and assessment of ETC complex I, II, and citrate
synthase activities in fibroblasts see the Supplementary
material.
Drosophila studies
For details of semi-quantitative RT-PCR of whole flies, meas-
urement of mitochondrial membrane potential, isolation of
Drosophila mitochondria and measurement of mitochondrial
respiration, and immunohistochemistry of the Drosophila
larval neuromuscular junction, see Supplementary material.
Stocks and culture conditions
Fly strains were obtained from the Bloomington Drosophila
Stock Center (Indiana, USA) and Vienna Drosophila
Resource Center (Austria). All transgenic insertions used in
this study were outcrossed at least five times into an isogenic
(iso31) background. These were: cg11576 UAS-RNAi (VDRC
7578, Dietzl et al., 2007; and HMC04813, Perkins et al.,
2015), and daughterless-GAL4 (Bloomington stock 55850).
Flies were reared at 25C on standard fly food consisting of
corn meal, yeast, sucrose, glucose, wheat germ, soya flour,
nipagin and propionic acid. For experiments with compound
supplementation, 0.1mg/ml riboflavin (Sigma) or 0.1mg/ml
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riboflavin-5’-lauric acid monoester (RLAM) was added to the
food. Flies were kept under 12-h light: 12-h dark cycles.
Quantification of flavins, ETC complex I, II, II/III
redox activities and citrate synthase assay
Riboflavin, FMN and FAD content, and ETC complex I, II
redox activity and citrate synthase activities were measured
in flies (10/genotype) as described above for patient fibro-
blasts. Prior to analysis all samples were subjected to three
cycles of freeze/thawing to lyse membranes. A Lowry assay
was used to normalize for protein concentration (Frolund
et al., 1995). Complex II/III activity was determined at 30C
using the method of King (1967), which followed the succin-
ate-dependent antimycin A sensitive reduction of cytochrome c
at 550 nm.
Electron microscopy of fly brains
Flies were decapitated and the heads were perfused with 3%
glutaraldehyde in 0.1M sodium cacodylate buffer and 5mM
CaCl2 overnight. Brains were then treated with 1% osmium
tetroxide for 3 h at 4C and embedded in Araldite CY212
resin. Thin sections were stained with toluidine blue and the
brain visualized with the light microscope. Ultrathin sections
(70 mm) were stained with lead citrate and uranyl acetate and
digital images taken on a Philips CM10 TEM with MegaView
G3 digital imaging system with Radius Software (Olympus).
Mitochondrial morphology was measured blind to genotype.
Larval behaviour
Larval locomotion was tested by placing individual third instar
larvae in the centre of petri dishes (8.5 cm diameter, 1.4 cm
height) coated with 10ml of 4% agar. On average, 30
larvae were tested per strain. The number of grid squares
(1 cm) entered per min by the larva was measured per each
genotype.
Adult behaviour
Adult flies were kept as groups of males and females in a
12 h:12 h light-dark cycle at 25C for 1 day prior to testing.
Single virgin females (1 day old) were loaded into glass tubes
(with 2% agar and 4% sucrose food) and monitored using the
Drosophila Activity Monitoring System (Trikinetics) in
12 h:12 h light-dark conditions at 25C with an approximate
intensity of 700–1000 lx during the light condition. For ex-
periments involving supplementation, riboflavin or RLAM was
added to the above food. Fly activities were deduced from the
number of times flies broke beams of infrared light passing
through the middle of the tube. Locomotor activity was re-
corded in 30-min bins and an analysis was performed on the
second day after loading. Data were pooled from at least two
independent experiments. The relative locomotor activities per
30-min bin for individual flies were averaged for each geno-
type and also the average locomotor activity per day was cal-
culated. Locomotion graphs were generated using GraphPad
Prism 6 and Microsoft Excel.
Life span
Adult female flies were collected from eclosion and transferred
to fresh food tubes (10 flies/tube) with or without RLAM sup-
plementation. Each day, death events were scored and viable
flies were transferred to fresh tubes. Survival proportions were
plotted as percentage of live flies against days. Approximately
100 flies were tested for each genotype.
Statistics
Statistics were performed using GraphPad Prism 6. The signifi-
cance between the variables was shown based on the P-value
obtained (ns indicates P4 0.05, *P50.05, **P50.005,
***P5 0.0005). Data are presented as box plots illustrating
80% of the data distribution, together with the median and
10th, 25th, 75th and 90th percentiles unless otherwise stated.
Results
Clinical and genetic analysis of
patients with BVVL syndrome
We screened 132 patients with phenotypes suggestive of
BVVL syndrome and identified 20 patients (15%) with
riboflavin transporter mutations. Genetic and clinical de-
tails of the 20 individuals carrying mutations in
SLC52A2 or SLC52A3 are summarized in Table 1.
Thirteen of the probands were males. Age of symptom
onset was available for 15 patients (mean: 8.2 years;
range: 7 months–21 years). First symptoms usually
occurred during childhood (11 patients) and less frequently
during teenage years (four patients) or adulthood (one pa-
tient), and were mostly secondary to cranial nerve involve-
ment (Table 1). Only one patient presented with symptoms
not related to cranial nerve involvement (limb weakness).
Sensorineural hearing loss was both a common presenting
symptom (eight patients) and a common clinical feature
during follow-up (17 patients). Other frequent clinical fea-
tures include optic atrophy (14 patients), weakness of facial
and bulbar muscles (13 patients) and sensorimotor periph-
eral axonal neuropathy (16 patients). Limb weakness was
more severe in the upper than in the lower limbs in nine
patients. Ten patients developed some degree of respiratory
involvement with three requiring assisted ventilation, and
10 patients had dysphagia and/or chewing difficulty, six of
them requiring nasogastric tube or gastrostomy feeding.
Of the 22 mutations identified, eight were found in the
SLC52A2 locus and 14 in SLC52A3, of which five
SLC52A2 and nine SLC52A3 variants were novel (Table
1). In contrast, no SLC52A1 mutations were observed.
None of the variants were found in the homozygous state
in the ExAC database of over 100 000 controls, suggesting
pathogenicity (Table 1). Consistent with this hypothesis, all
except one mutation (p.Arg212Cys in SLC52A3) were pre-
dicted to be at least probably damaging by SIFT and
PolyPhen-2 algorithms (scores ranging between 0.55 and
1). The mutations reside in transmembrane helices and in
the intracellular and extracellular loops. Although three
homozygous and seven compound heterozygous mutations
were identified, five mutations (all in SLC52A3) were iden-
tified on only one allele. These heterozygous individuals did
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not differ substantially in phenotype including age of pres-
entation from the rest of the cohort of mutation-positive
cases.
There was no correlation between the nature of patho-
genic variant and phenotype severity, although in the case
of Patient AM2, nonsense mutations on both alleles re-
sulted in a truncated protein, and this genotype correlated
with rapid progression of symptoms and death at 2 years
of age.
Neuropathological analysis of
patients with BVVL syndrome
To characterize in detail the neuropathological symptoms
of BVVL syndrome, we undertook a comprehensive patho-
logical examination of two patients carrying compound
heterozygous SLC52A3 mutations (Patients AM2 and
AM4; Table 1). These patients represent two ends of the
spectrum of severity of BVVL syndrome.
Patient AM2 had a normal birth at term. His motor skills
were mildly delayed and he never acquired the ability to
roll over completely front to back. He achieved the ability
to sit with minimal support at age 7 months. From about 8
months of age he began to exhibit more clear signs of the
condition such as ptosis and neck weakness. He was
admitted at the age of 9 months for investigations but no
diagnosis was made at that time. His condition quickly
progressed to include respiratory muscle weakness, and
ventilator dependence at the age of 1 year. He also de-
veloped severe weakness in his shoulder girdle areas and
proximal upper limbs. Weakness subsequently developed in
forearm muscles, distal lower limb muscles and thighs,
trunk and face, and progressed to the point that he could
only weakly move his eyelids and had very limited sideways
movements of his eyes. Nerve conduction studies and EMG
showed a severe neuropathy. He died at 2 years of age of
respiratory failure.
The cerebral cortex, hippocampus and cerebral white
matter were unremarkable. The deep grey nuclei were not
available for assessment. The neuronal density in the sub-
stantia nigra was normal for the patient’s age, but the third
and fourth cranial nerve nuclei showed severe neuronal
loss, gliosis and microglial activation (Supplementary
Fig. 1). In the pons there were two symmetrical sharply
demarcated lesions surrounding both fifth cranial nerves
(Fig. 1A–D). In these lesions we observed prominent neo-
vascularization, dense infiltration of macrophages and
widespread myelin loss, with relative preservation of
axons. The fifth cranial nerve was vacuolated and its nu-
cleus showed severe neuronal loss and gliosis
(Supplementary Fig. 1). In the medial lemniscus at the
level of the midbrain and pons there was prominent gliosis,
microglial activation and vacuolation of the neuropil,
which was also seen in the central tegmental tract. In the
medulla, the ninth, 10th and 12th cranial nerve nuclei
showed severe neuronal depletion and gliosis with paleT
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corresponding nerve tracts. The neuronal loss in the eighth
cranial nerve was moderate (Supplementary Fig. 1). The
medial lemniscus, spinocerebellar tract and medullary re-
ticular formation were all gliotic. Inferior olivary nuclei,
in particular the dorsal and ventral parts, showed severe
neuronal loss and gliosis. In the cerebellum, there was no
significant cortical atrophy [Supplementary Fig. 2B(i)], but
the cerebellar white matter showed widespread vacuolation.
In the middle cerebellar peduncle there was a lesion with
similar morphology to those seen in the pons and medulla.
In the spinal cord, there was moderate neuronal loss in the
anterior horns and moderately severe atrophy of
Figure 1 Pathological features of the symmetrical brain stem lesions and the comparison of the spinal cord nerve root
involvement in the Patient AM2. (A–D) Low power views of the pons and (A1–D2) high power views of the pontine lesion indicated with
green square boxes in A. (A–A2) The haematoxylin and eosin (H&E) stained section demonstrates sharply demarcated lesion surrounding the
fifth cranial nerve (black arrow). High power view (A2) reveals frequent small calibre blood vessels and foamy macrophages within the lesion.
(B–B2) Immunostaining for myelin with SMI94 antibody shows a near complete absence of myelin, whilst the axons (C–C2), demonstrated with
SMI31 antibody, are well preserved within the lesion. (D–D2) Immunostaining for macrophages with CD68 antibody confirm a dense infiltrate of
macrophage in the centre of the lesion. (E–H) Low power views of transverse sections of the sacral spinal cord. The posterior nerve roots are
indicated with blue square box in E and on high power views in E1–H1. The anterior nerve roots are indicated with red square box in E and on
high power views in E2–H2. (E1–G1) The posterior nerve roots are densely populated with myelinated fibres with (H1) minimal macrophage
activity. (E2–G2) In the anterior nerve roots there is a severe loss of myelinated fibres and (H2) widespread infiltration of macrophages. Scale
bar = 4 mm in A–D; 1.7 mm in E–H; 350 mm in A1–D1; 70mm in A2–D2; 140 mm in E1–H1 and E2–H2.
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spinothalamic tracts, spinocerebellar tracts, gracile fasciculus
and nucleus in the medulla, and to a lesser extent cuneate
fasciculus and nucleus in the medulla (Supplementary Fig.
1). There was severe fibre loss and macrophage activation in
the anterior spinal nerve roots, whilst the poster spinal nerve
roots were densely populated by myelinated fibres with little
macrophage activation (Fig. 1E–H).
Patient AM4 also had a normal birth at term. He had
hearing problems from the age of 8 years and was diag-
nosed with sensorineural hearing loss at the age of 11.
Figure 2 The spectrum of the atrophy in the cranial nerve nuclei, deep cerebellar nuclei and white matter tracts in Patient
AM4. (A) In the fifth cranial nerve nucleus there is a moderately severe neuronal loss and gliosis and accompanying myelinated fibre loss in the
nerve tract (inset). (B) The sixth cranial nerve nucleus shows only very mild neuronal loss and gliosis. (C) In the seventh and (D) eighth cranial
nerve nuclei the neuronal loss and accompanying gliosis is very severe. (E) In the nuclei of the 10th and (F) 12th cranial nerves the neuronal loss
and gliosis is moderately severe, but the nerve tracts (inset in E for the 10th nerve and inset in F for the 12th nerve) show marked depletion of
myelinated fibres. (G) In the cerebellar cortex there is widespread Purkinje cell loss, Bergmann gliosis and gliosis in the molecular cell layer.
(H) The globose nucleus shows a severe neuronal loss and gliosis, while (I) the neurons in the dentate nucleus are better preserved and gliosis is
mild. (J) The medial lemniscus in the medulla, (J1) the gracile fasciculus in the posterior column, (K) inferior cerebellar peduncle in hindbrain and
spinocerebellar tract in the spinal cord (K1) show severe gliosis and vacuolation of the neuropil on haematoxylin and eosin-stained sections, and
microglial activation on immunohistochemistry (not shown). (L and L1) The corticospinal tracts at the level of medulla (L) and spinal cord (L1) in
contrast is well populated by myelinated fibres with no apparent gliosis. Scale bar = 110 mm in A–F and H–L; 220 mm in G. (A–F) Stained with
Luxol fast blue. (G–I and J, J1–L, L1) Stained with haematoxylin and eosin.
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He developed optic atrophy and difficulty walking at the
age of 16 years. At age 17 years he presented with dysarth-
ria and subsequently developed swallowing difficulties.
EMG showed widespread denervation and nerve conduc-
tion studies were consistent with an axonal motor neur-
opathy. He died at 19 years of respiratory insufficiency.
The cerebral neocortex, hippocampus, amygdala, caudate
nucleus putamen, globus pallidus, thalamus and cerebral
deep white matter showed no apparent abnormality. Mild
gliosis was evident in the dorsal part of the optic tract. In
the midbrain, the substantia nigra was densely populated
by lightly pigmented neurons in keeping with the patient’s
age. The corticospinal tracts were unremarkable in the cere-
bral peduncles of the midbrain. The third cranial nerve
nucleus was not available for the assessment and the
fourth cranial nerve nuclei showed a mild degree of neur-
onal loss and accompanying mild gliosis (Supplementary
Fig. 3). In the pons there was prominent neuronal loss in
the loci coerulei with free pigment deposits in the neuropil
and gliosis (Supplementary Fig. 3). The neuronal density in
the pontine basal nuclei and the fibre density in the trans-
verse and corticospinal tracts were unremarkable. The su-
perior cerebellar peduncles showed mild gliosis and
vacuolation. The fifth and seventh cranial nerve nuclei
showed severe neuronal loss (Supplementary Fig. 3 and
Fig. 2A and C). In the sixth cranial nerve nucleus the gliosis
was mild and the neuronal density was relatively well-pre-
served (Fig. 2 and Supplementary Fig. 3). In the medulla
(Fig. 2D–F and Supplementary Fig. 3), the nuclei of the
eighth cranial nerve showed severe neuronal loss and prom-
inent gliosis and the nuclei of the 10th and 12th cranial
nerves and nucleus ambiguus showed moderately severe
neuronal loss and gliosis. The nerve tracts of the available
fifth, 10th and 12th cranial nerves (Fig. 2A, E and F, insets)
showed reduced density of the myelinated fibres. The gra-
cile nucleus showed severe, while the cuneate nucleus
showed mild neuronal loss and gliosis (Supplementary
Fig. 3). In the cerebellar cortex there was widespread
Purkinje cell loss and Bergmann gliosis and some degree
of neuronal loss in the granular cell layer [Fig. 2G and
Supplementary Fig. 2A(i)].
The cerebellar nuclei (fastigii, globosus and emboliformis)
showed severe neuronal loss and gliosis bilaterally, while the
dentate nuclei were mildly gliotic with less conspicuous neur-
onal loss (Fig. 2H–I). There was a severe pallor, gliosis and
prominent microglial/macrophage activation in the medial
lemniscus (Fig. 2J), spinothalamic tracts and inferior cerebel-
lar peduncles (Fig. 2K). The corticospinal tracts in the pyra-
mids (Fig. 2L) were densely populated by myelinated fibres
and the inferior olivary nuclei showed only mild patchy
gliosis (Supplementary Fig. 3). In the ventral aspect of the
upper spinal cord at the junction with the lower medulla
there were bilateral symmetric lesions involving the anterior
horns, lateral reticular nucleus, supraspinal nucleus, spi-
nothalamic tracts and medial longitudinal fasciculus (Fig.
3A–E). In these lesions there was neovascularization and
dense infiltration of macrophages with a near complete
loss of myelin, while neurons and axons were relatively pre-
served (Fig. 3A–E). Below these lesions the cervical cord
showed a severe atrophy of the neurons in the anterior
horns and to a lesser extent posterior horns
(Supplementary Fig. 3). There was a severe, slightly asym-
metrical atrophy of the uncrossed anterior corticospinal
tracts, whilst the lateral corticospinal tracts were densely
populated by myelinated fibres with only mild vacuolation
[Fig. 2L(i) and Supplementary Fig. 3]. Severe symmetrical
atrophy with prominent pallor, macrophage infiltration
and vacuolation of the anterior and posterior spinocerebellar
tracts [Fig. 2K(i)], spinothalamic tracts and gracile and to a
lesser extent cuneate fasciculi (Supplementary Fig. 3) was
also observed. While the posterior nerve roots were densely
populated by myelinated fibres with only mild macrophage
activation, in the anterior nerve roots there was moderately
severe loss of myelinated fibres and prominent infiltration of
macrophages (Fig. 3F–J).
Amyloid-b, hyper phosphorylated tau, -synuclein, TDP-43,
p62 or ubiquitin positive inclusions were not observed in
Patients AM2 and AM4. In both cases the inflammatory re-
action was restricted to microglial activation and macrophage
infiltrates with no significant lymphocytic inflammation.
Generation of a novel Drosophila
model of BVVL syndrome
Mitochondrial dysfunction has long been documented in
neurodegenerative diseases (Palomo and Manfredi, 2015).
For example, SOD1 mutations in familial ALS have been
shown to lead to abnormalities in mitochondrial morph-
ology, both in biopsies and post-mortem tissues of human
patients (Sasaki and Iwata, 2007; Sasaki, 2010) and in cel-
lular and mouse models of the disease (Magrane et al.,
2009, 2014; Vinsant et al., 2013; Palomo and Manfredi,
2015). However, whether mitochondrial function is per-
turbed by BVVL syndrome-linked mutations is unclear.
We hypothesized that lower levels of intracellular riboflavin
as a result of mutated riboflavin transporters would lead to
reduced levels of FMN and FAD, which in turn would lead
to impairments at the level of the ETC complex I and com-
plex II. We sought to test this hypothesis in vivo.
Previous work has used a knockout of the mouse
SLC52A3 orthologue to model BVVL syndrome (Intoh
et al., 2016; Yoshimatsu et al., 2016). However,
SLC52A3 knockout mice die within 48 h of birth, preclud-
ing phenotypic analysis at later developmental stages. To
circumvent this issue we turned to the fruit fly, Drosophila.
Comparative BLAST analysis revealed a single Drosophila
homologue of SLC52A3/hRFVT3, the previously uncharac-
terized gene cg11576 (E-value: 2.74  1074; next closest
homologue, E-value: 2.95). As described below, we name
the cg11576 gene drift (Drosophila riboflavin transporter).
The DRIFT amino acid sequence exhibits 36.9% identity
and 53.1% similarity with hRFVT3, and the L1 loop and
GXXXG motifs characteristic of riboflavin transporters are
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also conserved (Supplementary Fig. 4) (Russ and Engelman,
2000; Zhang et al., 2010). The L1 loop is a region of the
protein shown to recognize riboflavin through both hydro-
gen bonds and van der Waals interactions (Zhang et al.,
2010), while the GXXXG motif is required for dimeriza-
tion (Russ and Engelman, 2000). DRIFT is also highly
homologous to the hRFVT3 paralogues hRFVT1 and
hRFVT2 (Supplementary Fig. 4). Furthermore, 10/19 and
11/25 residues in hRFVT2 and hRFVT3, respectively, that
are altered by BVVL syndrome-linked mutations are either
identical or functionally similar in DRIFT (Supplementary
Fig. 4 and 5). Mammalian riboflavin transporters exhibit
wide domains of expression, including the nervous system,
intestine, testes, and placenta (Yonezawa and Inui, 2013).
Similarly, drift is transcribed in several adult Drosophila
tissues, including the head, gut, abdomen and thorax
Figure 3 Pathological features of the symmetrical brain stem and spinal cord lesions and the comparison of the spinal cord
nerve root involvement in the Patient AM4. (A–E) Low power views of the upper cervical cord and (A1–E1) high power views of the lesion
indicated with green square box in A. (A and A1) The haematoxylin and eosin (H&E) stained section demonstrates bilateral symmetrical sharply
demarcated lesions (indicated with a green square box on one side) in the anterior part of the upper cervical cord. High power view of the lesion
(A1) reveals intact neurons (blue arrow) within a dense infiltrate of foamy macrophages and increased numbers of small calibre blood vessels.
(B and B1) Staining for myelin with Luxol
 fast blue (LFB) special stain and (C and C1) immunostaining with SMI94 antibody highlights the
preservation of the neurons and shows complete absence of myelin, whilst the axons (D and D1), demonstrated with SMI31 antibody, are better
preserved within the lesion. (E and E1) Dense infiltrates of macrophages within the bilateral lesions are confirmed with CD68 immunohisto-
chemistry. (F–J) Low power views of transverse section of the thoracic spinal cord. The posterior nerve roots are indicated with blue square box
in F and on high power views in F1–J1. The anterior nerve roots are indicated with red square box in F and on high power views in F2–J2. (F1–I1)
The posterior nerve roots are densely populated with myelinated fibres with (J1) minimal macrophage activity. (F2–I2) In the anterior nerve roots
there is a moderately severe loss of myelinated fibres and (J2) prominent macrophage activation. Scale bars = 2.5 mm in A–E and F–J; 80mm in
A1–E1, F1–J1 and F2–J2.
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(Supplementary Fig. 6A). This broad expression pattern is
in agreement with RNAseq data from the Drosophila
ModEncode Project (Graveley et al., 2011).
To examine the biochemical and phenotypic conse-
quences of loss of DRIFT, we disrupted drift expression
using either P-element insertions or transgenic RNA inter-
ference (RNAi). Insertion of a MiMIC transposon
(cg11576MI04904-GFSTF.2) within intron 1 of drift resulted
in viable heterozygote adults but homozygote lethality
prior to the L3 larval stage. Furthermore, global knock-
down of drift using two independent transgenic RNAi
lines (7578 and HMC04813) driven via a strong global
promoter (actin-Gal4) also resulted in either complete or
highly penetrant lethality prior to the adult stage. Thus,
similarly to SLC52A3 (Yonezawa and Inui, 2013; Intoh
et al., 2016; Yoshimatsu et al., 2016), and consistent
with a fundamental requirement for riboflavin transport
in metazoans (Biswas et al., 2013), DRIFT is likely to be
essential in Drosophila.
Using a distinct global driver (daughterless-Gal4; da-
Gal4) in concert with the 7578 RNAi line, we achieved
robust drift knockdown as determined by semi-quantitative
RT-PCR (Supplementary Fig. 6C). However, this knock-
down did not result in early lethality (suggesting weaker
RNAi expression by da-Gal4 relative to actin-Gal4), facil-
itating analysis of drift knockdown flies at later develop-
mental stages. Using whole-body tissue from drift
knockdown adults and associated control lines (heterozy-
gotes for da-Gal4 or the drift RNAi transgene), we found
that drift knockdown resulted in a substantial reduction of
in vivo riboflavin levels as well as the riboflavin metabolites
FMN and FAD (Fig. 4A–C). These results, combined with
the high homology of DRIFT to hRFVT1–3, strongly sug-
gest that DRIFT is a bona fide riboflavin transporter.
We next asked whether drift knockdown resulted in
reduced mitochondrial activity. Indeed, ETC complex I ac-
tivity was significantly reduced by drift knockdown
(Fig. 4D), while ETC complex II and II-III activity exhibit
a trend towards lower levels, albeit non-significant (Fig. 4E
and F). Thus, ETC complex I activity appears particularly
sensitive to DRIFT expression.
We also tested whether similar reductions in riboflavin
metabolism and ETC activity could be observed in BVVL
syndrome patient tissue. Using fibroblasts derived from
BVVL syndrome patients with riboflavin transporter muta-
tions and healthy age-matched controls (Supplementary
material), we found a significant reduction in the intracel-
lular levels of FMN and FAD in patient fibroblasts when
grown in low extracellular riboflavin conditions
(Supplementary Fig. 7A and B). Levels of intracellular ribo-
flavin in patient fibroblasts frequently fell below the thresh-
old of detection under these conditions, but not in control
fibroblasts (data not shown), consistent with defective
riboflavin transport. Furthermore, we observed a significant
reduction in ETC complex I and complex II activity in
patient fibroblasts compared to controls (Supplementary
Fig. 7C and D). Taken together, the above in vivo and
in vitro data suggest a conserved role for riboflavin
transporters in regulating ETC activity, particularly ETC
complex I.
drift knockdown lowers mitochondrial
membrane potential and affects
respiratory chain activity
Given the reduced ETC complex I activity in drift knock-
down flies, we investigated whether loss of drift affected
mitochondrial membrane potential (m), an indicator of
mitochondrial health and function. Mitochondrial mem-
brane potential was assessed in the brains of 1-day-old
flies using tetramethylrhodamine, methyl ester (TMRM)
fluorescence and imaging with confocal microscopy. This
revealed a significant reduction in mitochondrial membrane
potential in drift knockdown brains compared to control
(Supplementary Fig. 8A).
We next isolated mitochondria from drift knockdown
and control flies and assessed respiratory chain activity by
measuring oxygen consumption using a Clark-type oxygen
electrode. The steps in respiration were compared using
substrates and inhibitors specific to individual respiratory
complexes. We found that drift knockdown leads to signifi-
cantly increased oxygen consumption in state 2 (ADP inde-
pendent) respiration, when using substrates for complex I
(5mM pyruvate and 5mM malate) but not substrates for
complex II (5mM succinate in the presence of 5 mM rote-
none; Supplementary Fig. 8B). The respiratory control ratio
(RCR) is the ratio of state 3 respiration (ADP stimulated)
to state 4 respiration (no ADP present), and is considered
an indication of the degree of coupling of mitochondrial
respiratory chain activity to oxidative phosphorylation
(Chance and Williams, 1955). RCR was significantly
lower in drift knockdown mitochondria compared to con-
trol flies (Supplementary Fig. 8C). Furthermore, the effi-
ciency of oxidative phosphorylation (measured as ratio
ADP/O) was also significantly lower in drift knockdown
mitochondria (Supplementary Fig. 8D). Collectively, these
results suggest that loss of drift activity reduces mitochon-
drial membrane potential as a result of mitochondrial
uncoupling.
DRIFT is required for normal mito-
chondrial morphology
Given the alterations in mitochondrial function resulting
from reduced DRIFT levels, we also assessed whether
mitochondrial morphology was regulated by DRIFT. To
do so, we used electron microscopy to enable ultrastruc-
tural examination of mitochondria within the neuropil re-
gions (axons, dendrites and synaptic domains) of the
adult nervous system in drift knockdown flies and an
associated control. Strikingly, we frequently observed
grossly abnormal mitochondria containing swollen vacu-
oles in drift knockdown neurons, coupled with fragmented
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Figure 4 Knockdown of the Drosophila riboflavin transporter homologue drift results in reduced ETC activity and abnormal
mitochondrial morphology. (A–C) Riboflavin (A), FMN (B) and FAD (C) levels in drift knockdown flies and controls normalized to total
protein levels. (D–F) Complex I (D), complex II (E) and complex II-III (F) activity in drift knockdown flies and controls. Complex activities are
normalized to citrate synthase (CS) activity. Data were generated from a minimum of three independent experiments; n = 10 for each genotype.
Individual measurements were performed in duplicates. (G) Representative electron micrographs showing ultrastructure of neuronal mito-
chondrial in drift knockdown and control adult fly brains. Red arrows indicate severely damaged mitochondria. Scale bar = 1 mm. (H) Neuronal
drift knockdown mitochondria display significant reductions in the area of the mitochondrial cristae. da4 + control: n = 295 mitochondria; drift
knockdown: n = 516. (I–J) Morphological analysis also reveals a larger proportion of abnormal mitochondria in the drift knockdown fly brains
compared to controls. Representative images of respective categories are shown in I. Scale bar = 0.5 mm. Proportion of mitochondria in each
category is shown in J. da 4 + control: n = 295 mitochondria; drift knockdown: n = 516. For A–F and H, data are presented as box plots
illustrating 80% of the data distribution. Tenth, 25th, median, 75th and 90th percentiles are shown for these and all subsequent box plots.
***P5 0.0005, ns = P4 0.05, one-way ANOVA with Dunnett’s post hoc test (A–F) or Mann-Whitney U-test (H).
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mitochondrial cristae and a concomitant reduction in the
area of mitochondrial cristae (Fig. 4G and H). Grouping
mitochondria from control and drift knockdown neurons
in three categories (exhibiting no, minor, or major mito-
chondrial swelling and cristae fragmentation) (Fig. 4I), we
found that morphologically normal mitochondria were
depleted in drift knockdown neurons, whereas the propor-
tion of mitochondria exhibiting gross structural defects
was greatly increased (Fig. 4J). Thus, we have identified
a profound neuronal endophenotype associated with
reduced riboflavin transporter expression: vacuolar mito-
chondria with fragmented cristae.
drift knockdown results in reduced
locomotion and lifespan in Drosophila
The viability resulting from drift knockdown via da-Gal4
allowed us to assess whether riboflavin transporter knock-
down impacts post-embryonic organismal phenotypes in a
manner consistent with BVVL syndrome pathology (Foley
et al., 2014; Manole et al., 2014). To test for locomotor
defects, we used the Drosophila activity monitor (DAM)
system to perform automated recordings of adult locomo-
tion, measured as the number of infra-red beam breaks
across a 24 h day/night cycle. Under 12 h light: 12 h dark
conditions, control 1–2 day old adult female Drosophila
exhibited peaks of activity at dawn and dusk, and relative
quiescence during the afternoon and night (Fig. 5A and B).
In contrast, peak activity and total beam breaks in drift
knockdown adults were substantially reduced (Fig. 5C
and D). Furthermore, drift knockdown resulted in greatly
reduced lifespan, with 99% mortality within 4 days post-
eclosion (Fig. 5E). As BVVL syndrome is an early-onset
disorder, we also tested for locomotor defects at earlier
stages of the Drosophila lifecycle. Indeed, we found that
drift knockdown third instar larvae also exhibit signifi-
cantly reduced locomotion, as measured by the number
of grid crosses per minute on an agar plate (Fig. 5F).
These Drosophila phenotypes mimic motor dysfunction
and early mortality observed in patients with BVVL syn-
drome, suggesting a conserved link between riboflavin
transporter dysfunction, locomotor strength and lifespan.
Recently, reductions in axonal length and transcrip-
tional signatures of altered cytoskeletal composition
were identified in BVVL syndrome iPSC-derived motor
neurons (Rizzo et al., 2017). To test for altered axonal
development and signatures of cytoskeletal dysfunction
in vivo, we examined the neuromuscular junction of
drift knockdown third instar larvae. Interestingly, despite
the clear reduction in locomotion in drift knockdown
larvae (Fig. 5F), motor neuron development appeared un-
perturbed. Motor neuron axons correctly innervated the
muscle surface and there was no reduction in the number
of synaptic boutons per motor neuron following drift
knockdown (Supplementary Fig. 9A and B). Mutations
in cytoskeletal components such as Ankyrin, Spectrin,
HTS/Adducin and Futsch (a microtubule-binding protein)
cause well-defined alterations in the morphology of larval
motor neurons. These include synaptic retraction (disas-
sembly of active zones and degradation of inter-bouton
axonal regions, leaving small isolated boutons) (Pielage
et al., 2005, 2008, 2011), aberrant filopodia-like protru-
sions (Pielage et al., 2011), or a reduction in synaptic
growth (Roos et al., 2000). As we did not observe similar
phenotypes at the neuromuscular junction of drift knock-
down larvae, we infer that cytoskeletal organisation is
grossly normal in this background, and therefore that
locomotor defects can initially occur in the absence of
altered synaptic development and/or neurodegeneration
following drift knockdown.
An esterified riboflavin derivative
rescues drift knockdown phenotypes
Since BVVL syndrome pathology can be partially amelio-
rated by riboflavin treatment, we asked whether locomotor
defects in drift knockdown flies could be rescued by sup-
plementing Drosophila culture medium with riboflavin
(0.1mg/ml). However, we found no enhancement of loco-
motor activity following riboflavin supplementation
(Supplementary Fig. 10A). Riboflavin is a water-soluble
vitamin that is easily excreted, leading to low bioavailabil-
ity and short half-life. Furthermore, since riboflavin trans-
porter expression is very low in drift knockdown flies
(Supplementary Fig. 6C), riboflavin in the Drosophila
haemolymph may fail to be transported into relevant cell
types. We sought to circumvent these issues using an ester-
ified derivative of riboflavin (riboflavin-5’-lauric acid
monoester; RLAM; 0.1mg/ml) that could act as a pro-
drug, likely diffuse into the intracellular space independ-
ently of riboflavin transporter function and be cleaved by
esterases to release active riboflavin (Fig. 6A). Strikingly,
food supplementation with RLAM resulted in heightened
locomotion (Fig. 6B–D) and an extension of lifespan (Fig.
6E) in drift knockdown flies. This rescue correlated with
substantially increased complex I activity (3-fold) follow-
ing RLAM supplementation (Fig. 6F). In contrast to drift
knockdown flies, RLAM did not induce a significant fold-
change in locomotor activity in control adults, suggesting
that RLAM is non-toxic at the concentration and time scale
of supplementation tested (Supplementary Fig. 10B).
The rescue of adult drift knockdown by RLAM is clearly
partial. For example, activity in drift knockdown flies fed
RLAM was still significantly lower than control flies fed
RLAM (beams breaks/24h: da 4 + controls = 1457  58,
n = 47; da4 drift RNAi = 415  27, n = 53; P50.0001,
Mann-Whitney U-test). We speculated that this partial
rescue might be due to the fact that during pupariation, a
period of substantial morphological growth and remodelling
in the lifecycle of holometabolous insects, pupae will not be
exposed to RLAM. Reduced intracellular riboflavin concen-
trations during pupariation may in turn impact critical
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aspects of development, resulting in adult flies that can only
be partially rescued by RLAM supplementation. If true, we
would expect to observe a more robust rescue with RLAM
during earlier phases of development, when larval
Drosophila are continually exposed to RLAM in the food.
Indeed, in drift knockdown L3 larvae fed RLAM, we
observed a rescue of larval locomotor activity to wild-type
levels (Fig. 6G). Similarly to adult flies, riboflavin supple-
mentation had no effect on the activity of drift knockdown
L3 larvae (Supplementary Fig. 10C). Thus, we hypothesize
that RLAM may represent a more efficient treatment
method for BVVL syndrome patients, since—in contrast to
riboflavin—cellular uptake of RLAM may still robustly
occur in the absence of functional riboflavin transporters.
Discussion
We expanded the spectrum of genetic defects in riboflavin
transporters identifying SLC52A2 and SLC52A3 mutations
in 15% of cases. It was previously noted that the distinct
phenotype of upper limb and axial weakness, hearing loss
and optic atrophy could be attributed only to patients har-
bouring SLC52A2 mutations (Foley et al., 2014). However,
in our cohort of 20 patients, mutations in both SLC52A2
and SLC52A3 resulted in similar phenotypes. SLC52A3
mutations were more frequent than mutations in
SLC52A2 in our cohort. This is in agreement with previous
reports where BVVL syndrome-linked mutations were pre-
dominantly found in SLC52A3 (Bosch et al., 2011; Manole
Figure 5 drift knockdown reduces locomotor activity and lifespan in adult Drosophila. (A–C) Locomotor activity over 24 h of driver
alone (A) and drift RNAi alone (B) controls, and drift knockdown flies (C). Data were derived from adult females. Mean values for each time point
are presented; error bars indicate standard error of the mean (SEM). ZT = zeitgeber time. Light bars: lights on, darks bars: lights off. (D) Total
activity over 24 h for each genotype. Data were generated in at least three independent experiments; n = 30 for each control and n = 16 for the
drift knockdown flies. (E) Percentage survival of drift knockdown flies and controls on normal food; n = 98 for each control and n = 99 for the drift
knockdown flies. (F) The number of grid breaks per min of wandering third instar larvae; n = 30 for each genotype. ***P5 0.0005, Kruskal-Wallis
test with Dunn’s post hoc test.
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and Houlden, 2015). The high proportion of patients nega-
tive for mutations in the known riboflavin transporters in-
dicates that novel genetic causes are yet to be found.
The neuropathology of BVVL syndrome has not been
fully characterized (Sathasivam, 2008; Malafronte et al.,
2013). In keeping with the spectrum of clinical findings,
severe depletion of neurons in multiple cranial nerve
nuclei, anterior horns of the spinal cord, cerebellar nuclei,
Purkinje cells in the cerebellum, and degeneration of optic
pathway, solitary tract, and spinocerebellar and pyramidal
tracts was seen along with an axonal neuropathy in the
sural nerve (Foley et al., 2014). Here we provide detailed
neuropathological assessment of the brains and spinal cords
in two patients with genetically confirmed mutations in the
SLC52A3 gene who fell at the two extremes of age of
presentation of BVVL syndrome. There was variably and
severe neuronal loss and gliosis in the brain stem cranial
nerve nuclei and anterior horns of the spinal cord with
accompanying nerve root atrophy, which reflects the spec-
trum of clinical symptomatology. While no correlation be-
tween the mutation type and severity of clinical phenotypes
was evident in the case series presented here, it is possible
that different mutations directly influence the length of the
disease and degree of atrophy of specific brain structures.
For example, the rapid deterioration and demise of Patient
AM2 due to formation of truncated protein originating
from nonsense mutations on both alleles may explain less
prominent atrophy of cerebellar Purkinje cells when com-
pared with Patient AM4, the atrophy of which may require
longer duration of the disease (Supplementary Fig. 2). In
both patients there were symmetrical lesions in the brain
stem characterized by prominent neovascularization, dense
infiltration of macrophages, loss of myelin and relative
preservation of neurons and axons. Although the
Figure 6 A riboflavin ester partially rescues the drift knockdown phenotypes. (A) Chemical structure of riboflavin and its ester
(RLAM). (B) Total locomotor activity over 24 h in drift knockdown grown on normal and RLAM-supplemented food. Data were generated in at
least three independent experiments; n = 37 and n = 52 drift knockdown given normal and RLAM-supplemented food, respectively. (C and D)
Mean locomotor activity over 24 h of drift knockdown flies grown on normal food (C) and RLAM-supplemented food (D). Values are presented as
a mean  SEM. ZT = zeitgeber time. Light bars: lights on, darks bars: lights off. (E) Percentage survival of drift knockdown flies grown on normal
and RLAM-supplemented food; n = 99 and n = 92 drift knockdown given normal and RLAM-supplemented food, respectively. (F) Complex I
activity in drift knockdown flies grown on normal and RLAM-supplemented food. Complex activity is expressed as a ratio to citrate synthase (CS)
activity. Data were generated in at least three independent experiments; n = 10 for each genotype. (G) The number of grid breaks per min of
wandering third instar larvae with and without RLAM supplementation; n = 20 for each genotype. **P5 0.005, ***P5 0.0005, ns = P4 0.05,
Mann-Whitney U-test (B and F) or Kruskal-Wallis test with Dunn’s post hoc test (G).
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anatomical distribution of the symmetrical lesions differed
in both cases (Supplementary Fig. 1 and 3), the morph-
ology of the lesions was identical in both cases and was
similar to the pathology seen in mitochondrial encephalo-
pathies (Tanji et al., 2001; Filosto et al., 2007). To the best
of our knowledge such lesions have not been documented
in any of the previous published cases of BVVL clinical
syndrome and link with the mitochondrial abnormalities
in Drosophila and patient fibroblasts.
Recent work has sought to model the effects of riboflavin
transporter mutations in iPSC-derived motor neurons from
patients with BVVL syndrome (Rizzo et al., 2017) or
SLC52A3 knockout mice (Intoh et al., 2016; Yoshimatsu
et al., 2016). Motor neurons can still be successfully differ-
entiated from embryonic stem cells derived from mice lack-
ing SLC52A3 (Intoh et al., 2016), suggesting that RFVT3
(the SLC52A3 gene product) is not required for motor
neuron development in culture. In contrast, Rizzo et al.,
(2017) recently identified reduced axonal growth and tran-
scriptional alterations in cytoskeletal factors, including neu-
rofilament genes, in iPSCS-derived motor neurons from
SLC52A3-BVVL syndrome patient cells. Our results are
inconsistent with the premise that cytoskeletal defects
occur in motor neurons of Drosophila larvae with reduced
DRIFT, and suggest that DRIFT is not required for devel-
opment of larval motor neurons, similar to findings for the
SLC52A3 knockout mouse (Intoh et al., 2016). We note
that the Drosophila genome lacks neurofilament genes, pre-
venting us from assessing the potential relevance of this
pathway to neuronal dysfunction in BVVL syndrome
model Drosophila. However, the fact that locomotor de-
fects and reduced lifespan still occur in drift knockdown
flies in the absence of neurofilaments suggest that add-
itional pathways are likely to contribute to neuronal dys-
function following loss of riboflavin transporter in flies, and
potentially mammals. Based on our findings in both patient
fibroblasts and Drosophila, we suggest that mitochondrial
dysfunction may represent one such pathway that impacts
neuronal signalling and viability in patients with BVVL
syndrome.
Although fibroblasts are non-neural cells and not particu-
larly vulnerable as a tissue, metabolic and mitochondrial
abnormalities are commonly studied in this cell type
(Distelmaier et al., 2009). We identified clear deficiencies
in the activities of ETC complex I and complex II in pa-
tient-derived fibroblasts relative to fibroblasts from healthy
controls. Interestingly, previous results have only shown
evidence of marginally decreased ETC complex I activity
in muscle cells from some SLC52A2 patients sensitive to
reduced riboflavin uptake (Foley et al., 2014).
Mitochondrial activity in different tissues and cell types
may thus be differentially sensitive to reduced riboflavin
uptake. Biochemical analysis of Drosophila drift knock-
down tissue is consistent with data derived from patient
fibroblasts, showing diminished levels of riboflavin, FMN
and FAD, and reduced complex I activity when expression
of the single Drosophila riboflavin transporter is perturbed.
This in turn led to reduced mitochondrial membrane po-
tential and abnormal mitochondrial respiratory chain
activity.
Strikingly, we also observed profound abnormalities in
mitochondrial ultrastructure in Drosophila neurons follow-
ing drift knockdown. In contrast to the Drosophila
genome, which encodes a single riboflavin transporter, the
human genome contains three riboflavin transporter para-
logs that exhibit partially overlapping expression domains,
including within the brain (Yonezawa and Inui, 2013;
www.human.brain-map.org). Given the potential for func-
tional redundancy between riboflavin transporters co-ex-
pressed in the same neuron, we hypothesize that similar
alterations in mitochondrial function and morphology in
patients with BVVL syndrome are most likely to occur in
neurons in which a single mutated riboflavin transporter is
expressed. It will be intriguing to document neuronal sub-
types with such unique riboflavin transporter signatures
and to assess whether these are preferentially sensitive to
corresponding riboflavin transporter mutations.
At the whole-organismal level, there was impairment in
locomotion at both the larval and adult stages of drift
knockdown flies, reminiscent of the limb weakness and
movement impairment of the BVVL syndrome patients.
Moreover, drift knockdown flies had severely reduced life
span, similar to untreated patients (Bosch et al., 2011). It is
interesting to note that these lifespan and locomotor defects
are rescued by ingestion of an esterified derivative of ribo-
flavin, since this provides further evidence that the pheno-
typic signatures of drift knockdown flies are linked to
riboflavin deficiency and consequent downstream metabolic
defects. RLAM fulfils the criteria for being a treatment tar-
geting energy metabolism, a fundamental mitochondrial
process, in addition to circumventing the disease-related
protein, features generally believed to be of great promise
(Lin and Beal, 2006; Xuan et al., 2013; Foley et al., 2014).
It was previously thought that defective mitochondria
occurs secondary to primary disease mechanism, but current
research suggests that mitochondrial dysfunction may play a
role in both onset and development of certain neurodegen-
erative diseases such as Alzheimer’s disease, Parkinson’s dis-
ease, Huntington’s disease and ALS, where decreases in one
or more mitochondrial complexes and corresponding oxida-
tive stress have been reported in cell or animal models
(Menzies et al., 2002; Hoglinger et al., 2003; Fukui and
Moraes, 2007; McInnes, 2013; Yamada et al., 2014;
Golpich et al., 2017). Our results from in vitro and in vivo
models of a childhood neuropathy are in line with these
findings, highlight a potential contribution of mitochondrial
dysfunction to BVVL syndrome pathology, and suggest
future therapeutic strategies based on esterified riboflavin.
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